Status:
RECRUITING
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
Lead Sponsor:
Mayo Clinic
Conditions:
Primary Sclerosing Cholangitis
Liver Transplant, Complications
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared wit...
Detailed Description
Primary sclerosing cholangitis (PSC), an immune-mediated, progressive cholestatic disease with no well-established pharmacologic treatment, has an annual incidence of 2.0 per 100,000 and is responsibl...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Adults aged 18-75 irrespective of gender who have undergone LT for PSC or PSC-related liver malignancy between 1 year and 7 years (inclusive) prior to study enrollment
- Absence of rPSC at time of study enrollment
- At least one of the following additional features that increase risk of rPSC
- LT performed for cholangiocarcinoma
- Concurrent inflammatory bowel disease
- Any episode of cytomegalovirus viremia in the post-transplant period before study enrollment
- Any episode of acute cellular rejection in the post-transplant period before the study enrollment
- If target enrollment of 40 patients is not achieved during the first 6 months of study, we will remove f(iii) inclusion criteria to expand enrollment to any patient meeting the other inclusion/exclusion criteria.
- Due to lab requirements, we will only enrol patients who are within a 3 hour driving distance of Mayo Clinic Arizona and/or are willing to travel to Mayo Clinic Arizona at 4 month intervals during the study at own cost.
- Exclusion criteria:
- Presence of ischemic cholangiopathy which can mimic rPSC
- LT performed for primary biliary cholangitis or autoimmune hepatitis, or PSC with overlapping primary biliary cholangitis or autoimmune hepatitis, which may recur after LT and confound assessment of cholestasis
- Unaddressed post-LT hepatic artery compromise (e.g thrombosis, stenosis) which can mimic rPSC
- History of total colectomy for curative treatment of ulcerative colitis which reduces risk of rPSC
- Baseline GFR \<30 ml/min which precludes administration of fenofibrate
- Previously known intolerance or allergy to fenofibrate
- Other clinically significant comorbid condition, including inability to provide consent and psychiatric conditions, which in the opinion of the study team, may interfere with patient treatment, safety, assessment, or compliance with the treatment
- Female participants that are pregnant or planning to become pregnant
Exclusion
Key Trial Info
Start Date :
April 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06905054
Start Date
April 15 2025
End Date
July 1 2028
Last Update
June 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259